Claims for Patent: 5,763,476

Summary for Patent: 5,763,476

Title:	Sublingual or buccal pharmaceutical composition
Abstract:	The invention relates to a sublingual or buccal pharmaceutical composition comprising trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4 ,5-c]pyrrole or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable auxiliaries suitable for use in sublingual or buccal compositions, and the use thereof for the manufacture of a sublingual or buccal pharmaceutical composition for the treatment of mental disorders, such as psychosis and schizophrenia.
Inventor(s):	Delbressine; Leonardus Petrus Carla (Nijmegen, NL), Wieringa; Johannes Hubertus (Heesch, NL)
Assignee:	Akzo Noble N.V. (Arnhem, NL)
Application Number:	08/693,064
Patent Claims:	1. A pharmaceutical composition comprising as a medicinally active compound: trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole or a pharmaceutically acceptable salt thereof; wherein the composition is a solid composition and disintegrates within 30 seconds in water at 37.degree. C. 2. The pharmaceutical composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable water-soluble or water-dispersable carrier material. 3. The pharmaceutical composition of claim 2, wherein the carrier material is partially hydrolysed gelatin. 4. A method for treating tension, excitation, anxiety, and psychotic and schizophrenic disorders, comprising administering sublingually or buccally an effective amount of a pharmaceutical composition comprising trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4, 5-c]pyrrole or a pharmaceutically acceptable salt thereof. 5. The pharmaceutical composition of claim 1, wherein the composition disintegrates within 10 seconds in water at 37.degree. C. 6. The composition of claim 1, further comprising one or more pharmaceutically acceptable auxiliaries selected from the group consisting of hydrolyzed dextran, dextrin, mannitol, algenates, polyvinyl alcohol, polyvinyl pyrrolidine and water soluble cellulose derivatives. 7. A pharmaceutical composition comprising trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4, 5-c]pyrrole or a pharmaceutically acceptable salt thereof; and pharmaceutically acceptable auxiliaries, wherein the composition is made by the process of a) providing an aqueous solution comprising said compound and a water soluble or water dispersable carrier material; b) transferring the composition of a) into a mold; c) freezing the composition in the mold; and d) subliming the solvent by freeze-drying. 8. A pharmaceutical composition comprising trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4, 5-c]pyrrole maleate, mannitol, and gelatin. 9. The method of claim 4, wherein the composition is a solid pharmaceutical composition which rapidly disintegrates in the mouth of a subject upon insertion into the buccal pouch or upon placement under the tongue. 10. The method of claim 4, wherein the pharmaceutical composition further comprises pharmaceutically acceptable auxiliaries selected from the group consisting of hydrolyzed dextran, dextrin, mannitol, algenates, polyvinyl alcohol, polyvinyl pyrrolidine and water soluble cellulose derivatives. 11. The method of claim 10, wherein the pharmaceutically acceptable auxiliary is partially hydrolyzed gelatin. 12. The method of claim 4 wherein the pharmaceutical composition comprises trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4, 5-c]pyrrole maleate, mannitol, and gelatin. 13. A method for treating antihistamine and antiserotonin related diseases comprising administering sublingually or buccally an effective amount of a pharmaceutical composition comprising trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4, 5-c]pyrrole or a pharmaceutically acceptable salt thereof.